Partnology https://validator.w3.org/feed/docs/rss2.html Pranav Sharma, Founder and CEO of Xosomix Cellares raises $257M Series D, Eikon files for IPO, Tenpoint wins FDA approval Ray raises $125M Series B, Soleno sells Neurocrine for $2.9B, Kyverna reports CAR-T breakthrough Rev Med prices $2B public raise, Terremoto raises $108M Series B, Kailera raises record $625M IPO Sidewinder raises $137M Series B, Gilead acquires Tubulis, Biotech VCs embrace risk again Infinimmune lands $838M Merck deal, Neurocrine acquires Soleno, Aurinia aquires Kezar Triangle raises $4M for AI, Blackstone $6.3B life sciences fund, Gilead $1.68B T-cell engager deal with Ouro R1 Therapeutics raises $77.5M Series A, Gossamer cuts 48%, Kali scores $180M deal with Sanofi Breakout Ventures $114M fund, Alto Neuro raise $120M, f5 Therapeutics shuts down Day One acquired by Servier for $2.5B, Tenaya partners with Alnylam in $1.13B deal Atrium launches with $270M, BioAtla lays off 70%, biopharma VC surges Evommune $125M private placement, Ultragenyx layoffs, Gilead licensing deal with Genhouse Angitia raises $130M Series D, Iambic AI drug discovery deal, SpyGlass $150M IPO debut Leigh Hsu, Cofounder & CEO of Atticus Pharma Insights Mendra launches with $82M Series A, RAPT acquired by GSK, Janux signs deal with BMS Soley raises $200M Series C, Lux Capital raises $1.5B fund, Cartography signs $850M+ deal with Pfizer Faeth reverse merger with Sensei, Products peptide deal with Novartis, Vir partners with Astellas Dynavax acquired by Sanofi, Ultragenyx late-stage failure, Crinetics posts strong sales Ambros launches with $125M, Clavis forms $7.25B collaboration with Fosun, BioMarin acquires Amicus Chai Discovery raises $130M Series B, Dren Bio lands $100M Sanofi deal, Arthrosi acquired by Sobi Immix raises $100M, Mirum acquires Bluejay, FDA moves to phase out primate testing Cyril De Colle, Cofounder & CSO at Neurogastrx Samuel Collins, CMO at Mahzi Therapeutics Aspen Neuro raises $115M, Gilead acquires Sprint Bio, Cytokinetics nears FDA approval Solve raises $120M, Metagenomi cuts 25% of staff, Day One acquires Mersana Braveheart Bio raises $185M, A2 Bio CAR-T complete response in lung cancer, Rigel loses Eli Lilly partnership Genentech cuts 118 roles, Neurocrine signs $880M deal with TransThera, Evommune targets $150M IPO Profluent partners with Lilly in $2.25B deal, Candid acquires UCB, Protagonist $475M payout Craig Parker, CEO of Surrozen John Langowski, CSO at Micoy Therapeutics Protego raises $130M Series B, Cormorant targets $400M Fund Atlas Venture raises $400M, Braveheart Bio licenses $1B+ cardio drug, FDA vaccine advisory shakeup Chorom Pak, CEO of LynxBio Michael Mahler, CSO of Exagen John Fair, CEO of J3 Bioscience Electra raises $183M, Akero aquired by Novo, MapLight lands $250M IPO Kardigan raises $254M, Kezar plans layoffs, Kite and Pregene ink $1.52B cell therapy deal Apogee raises $345M, Ascenta Capital closes $325M fund, MapLight files for IPO TCGX Raises $1.3B Fund, BridgeBio spins out GondolaBio with $300M, Halozyme acquires Elektrofi Ridge Bio launches with $25M, LB Pharma $285M IPO, aTyr Pharma stock drops 80% Avenzo raises $60M Series B, ArsenalBio halves workforce, Kalexo Bio $1B licensing deal Mission BioCapital raises $134M for biotech fund, Sanofi Ventures expands biotech investment, 89bio acquired by Roche Camilla Simpson, CEO of Zehna Therapeutics Derrell Porter, CEO of cTRL Therapeutics Patient Square Capital $3.1B fund, Replicate lands $550M Novo deal, Enlaza partners with Vertex Gary Li, Chief Strategy / Scientific Officer, Venture Advisor Arnatar emerges from Stealth, Kite aquires Interius Bio, Ionis wins FDA approval Kriya raises $313M, Oric lays off 20%, Kumquat strikes $1.3B deal with Bayer Partnology